Targets › OPRK1
24 programs from 23 companies in 105 trials: 38 Phase 4, 35 Phase 2, 16 Phase 3, 16 Phase 1; Psychiatry, Other, Neurology; next expected readout Nov 2026.
G protein-coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of…. (UniProt, P41145)
Open in Phaseline: the race on OPRK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Peking University First Hospital | Anrikefon Selective peripheral κ-opioid receptor agonist | OPRK1 | Phase 4 | Laparoscopic Surgery | Mar 2027 |
| New York State Psychiatric Institute | Olanzapine-samidorphan Atypical antipsychotic (D2 dopamine receptor antagonist) combined with opioid antagonist ( | DRD2, OPRK1 | Phase 4 | Schizophenia Disorder | Apr 2027 |
| Zhongshan Ophthalmic Center, Sun Yat-sen University | Anrikefon peripherally-restricted KOR agonist | OPRK1 | Phase 4 | Ophthalmic Surgery | Dec 2027 |
| Currax Pharmaceuticals | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Obesity | Jan 2029 |
| Middle Tennessee Research Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Low Back Pain | – |
| University of Colorado, Denver | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Harm Reduction | – |
| Friends Research Institute, Inc. | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| Pouya Azar | Naloxone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 4 | Opioid Use Disorder | – |
| University of Maryland, Baltimore | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Opioid Use Disorder; Pain | Nov 2026 |
| Adneuris Therapeutics | Cebranopadol Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist | OPRL1, OPRK1, OPRD1, OPRM1 | Phase 3 | Pain; Chronic Pain | Jan 2027 |
| Trevi Therapeutics | Nalbuphine Opioid receptors; mu/kappa/delta agonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute … | Aug 2027 |
| AgelessRx | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 3 | Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug … | – |
| Alkermes | Samidorphan Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist | OPRM1, OPRK1, OPRD1 | Phase 3 | Schizophrenia | – |
| Tianjin Medical University Cancer Institute and Hospital | Anruikefen Peripherally selective kappa receptor agonist | OPRK1 | Phase 2 | Gastrectomy | Dec 2026 |
| Medical University of Lublin | Naltrexone Hydrochloride Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Vulvodynia | Dec 2026 |
| New York State Psychiatric Institute | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Jan 2027 |
| Tioga Pharmaceuticals | Asimadoline (TP0052) Kappa opioid receptor agonist | OPRK1 | Phase 2 | Vasomotor Symptoms | Oct 2027 |
| University of British Columbia | Naloxone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 2 | Opioid-use Disorder | Dec 2027 |
| Vifor Fresenius Medical Care Renal Pharma | Difelikefalin Kappa opioid receptor agonist | OPRK1 | Phase 2 | Pruritus | Aug 2029 |
| ReacX Pharmaceuticals | Nalmefene Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist | OPRM1, OPRD1, OPRK1 | Phase 1 | Opioid Abuse and Addiction; Behavioural Addiction | Dec 2026 |
| Johnson & Johnson (Janssen) | Aticaprant (JNJ-67953964) Kappa opioid receptor antagonist | OPRK1 | Phase 1 | Schizophrenia | Jun 2027 |
| Boulder Care | Buprenorphine Mu opioid receptor agonist; Kappa opioid receptor agonist | OPRM1, OPRK1 | Phase 1 | Opioid Use Disorder; Postoperative Pain; Pain, Postoperative; Acute Postoperative Pain … | Aug 2027 |
| Akyso Therapeutics | Naltrexone Opioid receptors; mu/kappa/delta antagonist | OPRK1, OPRD1, OPRM1 | Phase 1 | Opioid Use Disorder | Oct 2029 |
Opioid Use Disorder (23) Opioid-use Disorder (5) Alcohol Use Disorder (5) Opioid Use Disorder (OUD) (3) Analgesia (3) Schizophrenia (3) Idiopathic Pulmonary Fibrosis (2) Pain (2) Pain, Postoperative (2) Chronic Pain (2) Head and Neck Squamous Cell Carcinoma (2) Gastrectomy (1)
small molecule (21), mixed (2)
New York State Psychiatric Institute (2) Tianjin Medical University Cancer Institute and Hospital (1) Middle Tennessee Research Institute (1) Trevi Therapeutics (1) Currax Pharmaceuticals (1) University of British Columbia (1) AgelessRx (1) ReacX Pharmaceuticals (1) Akyso Therapeutics (1) University of Maryland, Baltimore (1) Boulder Care (1) Pouya Azar (1) Peking University First Hospital (1) University of Colorado, Denver (1) Friends Research Institute, Inc. (1) Zhongshan Ophthalmic Center, Sun Yat-sen University (1) Adneuris Therapeutics (1) Medical University of Lublin (1) University of Pennsylvania (1) Johnson & Johnson (Janssen) (1)
OPRM1 (17) OPRD1 (16) DRD2 (1) OPRL1 (1) CHRNA4 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.